Health Canada announced early last week that they have approved a new antipsychotic medication for the treatment of schizophrenia in adults.
The medication is called Invega Trinza (aka paliperidone palmitate), a new version of the drug Invega Sustenna, which has already been out on the market for some time. Psychiatrists are hopeful regarding the impact Invega Trinza may have on the care of their patients and specifically their medication compliance and risk of relapse, as it is an injection that need only be administered four times a year, rather than on a monthly schedule in its old form.
"Adherence to medication is often a challenge for Canadians living with schizophrenia, with not taking medication as prescribed as the most common cause of relapse. Studies have shown that within the first five years of treatment, up to 80 per cent of people with schizophrenia had experienced one or more relapses. Each relapse can result in a reduced response to treatment, putting continued symptom control even further out of reach.
"Relapse prevention is a critical part of disease management and recovery-focused care for people living with schizophrenia," says Dr. Philip Tibbo, Director, Nova Scotia Early Psychosis Program in Halifax. "The unique dosing of INVEGA TRINZA can offer patients long-term symptom control. This could help to significantly reduce the risk of relapse over time."
For more information about this new medication, check out the links below:
The medication is called Invega Trinza (aka paliperidone palmitate), a new version of the drug Invega Sustenna, which has already been out on the market for some time. Psychiatrists are hopeful regarding the impact Invega Trinza may have on the care of their patients and specifically their medication compliance and risk of relapse, as it is an injection that need only be administered four times a year, rather than on a monthly schedule in its old form.
"Adherence to medication is often a challenge for Canadians living with schizophrenia, with not taking medication as prescribed as the most common cause of relapse. Studies have shown that within the first five years of treatment, up to 80 per cent of people with schizophrenia had experienced one or more relapses. Each relapse can result in a reduced response to treatment, putting continued symptom control even further out of reach.
"Relapse prevention is a critical part of disease management and recovery-focused care for people living with schizophrenia," says Dr. Philip Tibbo, Director, Nova Scotia Early Psychosis Program in Halifax. "The unique dosing of INVEGA TRINZA can offer patients long-term symptom control. This could help to significantly reduce the risk of relapse over time."
For more information about this new medication, check out the links below:
RSS Feed
